Antiangiogenic drugs and advanced proliferative diabetic retinopathy
Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we discuss aspects related to the adjuvant use of these drugs in vitrectomy for complications of diabetic retinopathy. Bevacizumab shows beneficial effects regarding the surgical technique facilitation, but its long-term benefit still needs to be studied.
Main Authors: | , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Conselho Brasileiro de Oftalmologia
2011
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492011000200017 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0004-27492011000200017 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0004-274920110002000172011-07-11Antiangiogenic drugs and advanced proliferative diabetic retinopathyRibeiro,Jefferson Augusto SantanaMessias,AndréJorge,Rodrigo Anti-angiogenic drugs Vitrectomy Diabetic retinopathy Retinal detachment Vitreous hemorrhage Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we discuss aspects related to the adjuvant use of these drugs in vitrectomy for complications of diabetic retinopathy. Bevacizumab shows beneficial effects regarding the surgical technique facilitation, but its long-term benefit still needs to be studied.info:eu-repo/semantics/openAccessConselho Brasileiro de OftalmologiaArquivos Brasileiros de Oftalmologia v.74 n.2 20112011-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492011000200017en10.1590/S0004-27492011000200017 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Ribeiro,Jefferson Augusto Santana Messias,André Jorge,Rodrigo |
spellingShingle |
Ribeiro,Jefferson Augusto Santana Messias,André Jorge,Rodrigo Antiangiogenic drugs and advanced proliferative diabetic retinopathy |
author_facet |
Ribeiro,Jefferson Augusto Santana Messias,André Jorge,Rodrigo |
author_sort |
Ribeiro,Jefferson Augusto Santana |
title |
Antiangiogenic drugs and advanced proliferative diabetic retinopathy |
title_short |
Antiangiogenic drugs and advanced proliferative diabetic retinopathy |
title_full |
Antiangiogenic drugs and advanced proliferative diabetic retinopathy |
title_fullStr |
Antiangiogenic drugs and advanced proliferative diabetic retinopathy |
title_full_unstemmed |
Antiangiogenic drugs and advanced proliferative diabetic retinopathy |
title_sort |
antiangiogenic drugs and advanced proliferative diabetic retinopathy |
description |
Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we discuss aspects related to the adjuvant use of these drugs in vitrectomy for complications of diabetic retinopathy. Bevacizumab shows beneficial effects regarding the surgical technique facilitation, but its long-term benefit still needs to be studied. |
publisher |
Conselho Brasileiro de Oftalmologia |
publishDate |
2011 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492011000200017 |
work_keys_str_mv |
AT ribeirojeffersonaugustosantana antiangiogenicdrugsandadvancedproliferativediabeticretinopathy AT messiasandre antiangiogenicdrugsandadvancedproliferativediabeticretinopathy AT jorgerodrigo antiangiogenicdrugsandadvancedproliferativediabeticretinopathy |
_version_ |
1756373142840803328 |